Glenmark claims Napo's termination of crofelamer deal baseless
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals believes that Napo's termination of a pact concerning the anti-secretary gastrointestinal agent, crofelemer, is without basis and has sought an interim order from a US arbitration panel against Napo over the issue.